ClinicalTrials.gg

Program

Ranolazine

Also written as “Test formulation (Ranolazine extended-release tablets)”, “Reference formulation (Ranolazine extended-release tablets)” and “Ranolazine 500 mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Angina Pectoris · Atrial Fibrillation · Coronary Artery Disease · Cardiovascular Diseases, led by 7 companies.

Furthest: phase 4, since Mar 24, 200825 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences180 open or runningphase 4since Mar 24, 2008Sep 8, 2004none ahead
Menarini Group20 open or runningphase 2since Feb 10, 2012Feb 10, 2012none ahead
Amit Malhotra, MD10 open or runningphase 4since Jan 26, 2017Jan 26, 2017none ahead
Haisco Pharmaceutical Group10 open or runningphase 1since Jun 27, 2025Jun 27, 2025none ahead
Novartis10 open or runningphase 2since Mar 21, 2012Mar 21, 2012none ahead
OBS Pakistan10 open or runningphase 4since Mar 15, 2018Mar 15, 2018none ahead
TSH Biopharm10 open or runningno phasesince Jan 7, 2018Jan 7, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Sep 8, 2004.

  1. Nov 11, 2011Phase 3 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01472185 · 465 enrolled · United States, Czech Republic, Hungary and more
  2. Dec 15, 2011Phase 3 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01494987 · 431 enrolled · United States, Czech Republic, Hungary and more
  3. Jan 18, 2012Phase 2 study in Atrial FibrillationGilead Sciences · NCT01522651 · 134 enrolled · United States, Germany, Israel and more
  4. Feb 10, 2012Menarini Group's first study: phase 2 study in Atrial FibrillationNew to Menarini GroupMenarini Group · NCT01534962 · 241 enrolled · Germany, Italy, Spain and more
  5. Feb 14, 20122 phase 1 studies in Diabetes Mellitus, Type 2Gilead Sciences · NCT01546597, NCT01546558
  6. Mar 13, 2012Phase 3 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01555164 · 442 enrolled · United States, Canada, Czech Republic and more
  7. Mar 21, 2012Novartis's first study: phase 2 study in Cardiovascular DiseasesNew to NovartisNovartis · NCT01562041 · 14 enrolled · United States
  8. Jul 26, 2012Phase 1 study in Renal InsufficiencyGilead Sciences · NCT01675973 · 4 enrolled · United States
  9. Apr 17, 2013Phase 1 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01843127 · 24 enrolled · United States
  10. Apr 29, 2016Phase 1 study in Healthy Male IndividualsMenarini Group · NCT02817932 · 120 enrolled · Korea, Republic of
  11. Jan 26, 2017Amit Malhotra, MD's first study: phase 4 study in Angina PectorisNew to Amit Malhotra, MDAmit Malhotra, MD · NCT03044964 · 40 enrolled · United States
  12. Jan 7, 2018TSH Biopharm's first study: no phase study in Angina PectorisNew to TSH BiopharmTSH Biopharm · NCT03401502 · 20 enrolled · Taiwan
  13. Mar 15, 2018OBS Pakistan's first study: phase 4 study in Angina, StableNew to OBS PakistanOBS Pakistan · NCT03486561 · 2,000 enrolled
  14. Jun 27, 2025Haisco Pharmaceutical Group's first study: phase 1 study in HealthyNew to Haisco Pharmaceutical GroupHaisco Pharmaceutical Group · NCT07054255 · 72 enrolled · China

TargetBeta

SCN4A →SCN5A →read by rule
“Sodium channel protein type V alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07054255Healthy · China1CompletedHaisco Pharmaceutical GroupNov 9, 202072
NCT03486561Angina, Stable4UNKNOWNOBS PakistanSep 30, 20182,000
NCT03401502Angina Pectoris · Taiwan–CompletedTSH BiopharmMar 30, 201920
NCT03044964Angina Pectoris · United States4UNKNOWNAmit Malhotra, MDOct 201740
NCT02817932Healthy Male Individuals · Korea, Republic of1UNKNOWNMenarini GroupJul 2016120
NCT01843127Diabetes Mellitus, Type 2 · United States1CompletedGilead SciencesSep 201324
NCT01675973Renal Insufficiency · United States1TerminatedGilead SciencesAug 20124
NCT01562041Cardiovascular Diseases · United States2TerminatedNovartisJan 2, 201414
NCT01555164Diabetes Mellitus, Type 2 · United States, Canada, Czech Republic and more3CompletedGilead SciencesSep 2013442
NCT01546558Diabetes Mellitus, Type 2 · United States1CompletedGilead SciencesMar 201225
NCT01546597Diabetes Mellitus, Type 2 · United States1CompletedGilead SciencesMar 201224
NCT01534962Atrial Fibrillation · Germany, Italy, Spain and more2CompletedMenarini GroupOct 2013241
NCT01522651Atrial Fibrillation · United States, Germany, Israel and more2CompletedGilead SciencesMar 10, 2014134
NCT01494987Diabetes Mellitus, Type 2 · United States, Czech Republic, Hungary and more3CompletedGilead SciencesAug 2013431
NCT01472185Diabetes Mellitus, Type 2 · United States, Czech Republic, Hungary and more3CompletedGilead SciencesOct 2013465
NCT01442038Coronary Artery Disease · United States, Austria, Belgium and more3CompletedGilead SciencesFeb 20152,651
NCT01425359Angina Pectoris · United States, Belarus, Bulgaria and more4CompletedGilead SciencesOct 2012949
NCT01334203Angina Pectoris4WithdrawnGilead SciencesOct 20120
NCT01221272Myocardial Ischemia · United States, Canada, Czech Republic and more4CompletedGilead SciencesSep 201281
NCT01163721Diabetes Mellitus, Type 2 · United States2CompletedGilead SciencesNov 201080
NCT01163734Heart Failure, Diastolic · Germany2CompletedGilead SciencesFeb 201120
NCT00832572Coronary Artery Disease · United States4TerminatedGilead SciencesJun 20095
NCT00644332Chronic Angina · United States4CompletedGilead SciencesJan 2011172
NCT00099788Myocardial Ischemia · United States3CompletedGilead SciencesFeb 20076,560
NCT00091429Angina Pectoris3CompletedGilead SciencesFeb 2005500

How it is read

Names in the registry

  • “Ranolazine”, 24 entries
  • “Test formulation (Ranolazine extended-release tablets)”, 1 entry
  • “Reference formulation (Ranolazine extended-release tablets)”, 1 entry
  • “Ranolazine 500 mg”, 1 entry
  • “Ranolazine plus Metoprolol Combination”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.